Physician profile
Raja E Lewis
NPI 1558479469
$5,136.97
in general payments reported to CMS, 2019-2025
23 companies · $1,357 in 2025
The $1,357 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,409 · 2020: $182 · 2021: $907 · 2022: $234 · 2023: $142 · 2024: $906 · 2025: $1,357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,405.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,404.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,592.39 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $754.93 | 2019-2025 | Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $448.94 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $318.42 | 2021-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $317.22 | 2021-2025 | Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $226.97 | 2019-2023 | Jardiance |
| Ardelyx, INC. | $214.05 | 2024-2025 | Ibsrela |
| Amgen INC. | $169.04 | 2024-2025 | Evenity, Tavneos, Prolia |
| Phathom Pharmaceuticals, INC. | $163.64 | 2024 | Voquezna |
| Astellas Pharma US INC | $152.27 | 2019-2023 | Veozah, Myrbetriq |
| Urovant Sciences INC | $125.00 | 2021 | |
| Sumitomo Pharma America, INC. | $99.91 | 2023-2025 | Gemtesa |
| Shield Therapeutics INC | $91.14 | 2022-2025 | Accrufer |
| Dexcom, INC. | $77.55 | 2021-2025 | Dexcom G6 Transmitter |
| Bsn Medical INC | $72.37 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $54.84 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $51.74 | 2022 | |
| Abbvie INC. | $51.56 | 2023-2025 | |
| Ironwood Pharmaceuticals, INC | $50.31 | 2019 | |
| Allergan, INC. | $34.63 | 2019 | |
| Merck Sharp & Dohme LLC | $28.63 | 2019 | |
| Abbott Laboratories | $24.28 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raja Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.